Understanding Key Drivers and Growth Opportunities in the Viral And Non-Viral Vector Manufacturing Market: Trends and Market Size Insights
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Factors Are Propelling the Market Growth of theViral And Non-Viral Vector Manufacturing Market from 2025 to 2034?
The escalating frequency of inherited diseases is anticipated to fuel the expansion of the viral and non-viral vector manufacturing markets in the future. Genetic abnormalities often occur due to alterations in the normal DNA sequence. Viral vectors serve the role of introducing therapeutic genes to target cells, effectively substituting or enhancing the flawed genes responsible for genetic abnormalities. Non-viral vectors, on the other hand, commonly feature in ex vivo gene therapy methods where cells undergo genetic manipulation outside the body before reintroduction into the patient. For instance, data from the International Diabetes Federation, a Belgium-based diabetes organization, revealed in June 2022, that global diabetes prevalence had risen to 10.5%, with over half (44.7%) of the people affected remaining undiagnosed and an estimated 783 million adults, or one in eight people, projected to develop diabetes by 2045. Consequently, the growing occurrence of inherited diseases stimulates the expansion of the viral and non-viral vector manufacturing market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp
What is the Predicted Annual Growth Rate of theViral And Non-Viral Vector Manufacturing Market Impact Industry Trends by 2034?
There has been a swift expansion in the size of the viral and non-viral vector manufacturing market in the past few years. It is projected to grow from a value of $8.67 billion in 2024 to around $10.3 billion in 2025, with a compound annual growth rate (CAGR) of 18.8%. The growth experienced in the past was influenced by various factors including increased occurrences of genetic disorders, advancements in the field of biotechnology, higher investment in gene therapy research, an upsurge in the understanding of personalized medicine, and regulatory backing for the development of gene therapy.
The market for manufacturing both viral and non-viral vectors is projected to experience significant expansion in the forthcoming years. The market is predicted to reach a value of $22.06 billion by 2029, featuring a compound annual growth rate (CAGR) of 21.0%. This surge over the forecast period can be traced back to a growing demand for gene therapies, a rise in uses for treating uncommon diseases, escalating investments made in biomanufacturing infrastructure, and an increase in precision medicine usage. Some emerging trends for this period encompass the creation of next-generation viral vectors, an upswing in the employment of technology like CRISPR or cas9 in the manufacture of vectors, an emphasis on scalable and cost-efficient production processes, a surge in adopting non-viral vectors, and strides made in cell and gene therapy manufacturing techniques.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12570
How Are Market Trends and Innovations Revolutionizing theViral And Non-Viral Vector Manufacturing Industry in Recent Times?
The rise of technological innovations is seen as a primary trend gaining traction in the viral and non-viral vector manufacturing markets. Established companies within these markets are introducing technologically forward solutions to maintain their standing. For example, Merck KGaA, a scientific and tech company based in Germany, unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform in August 2022. Recognized as one of the earliest Contract development and manufacturing organizations and technology developers to provide a comprehensive viral vector manufacturing suite, encompassing AAV, Lentiviral, CDMO, CTO, and process development. This groundbreaking platform enables biopharmaceutical firms to reduce process development time and cost, thereby fast-tracking the clinical manufacture timeline.
Which Key Market Players Are Shaping the Future and Growth of theViral And Non-Viral Vector Manufacturing Market?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
Order Your Report Now For A Swift Delivery:
#thebusinessresearchcompany #marketresearch #marketintelligence
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp
What Regions Are Dominating the Viral And Non-Viral Vector Manufacturing Market Growth?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Viral And Non-Viral Vector Manufacturing Maret 2025, By The Business Research Company:
Viral Vectors And Plasmid DNA Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Antivirals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Antiviral Combination Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
